Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 43, 2013 - Issue 5
Submit an article Journal homepage
830
Views
29
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans

Shinji FurutaPharmaceutical Research Laboratories, Sanwa Kagaku Kenkyusho, Co. Ltd, Mie, JapanCorrespondence[email protected]
,
Clair SmartDepartment of Drug Metabolism, Huntingdon Life Sciences, Huntingdon, Cambridgeshire, UK
,
Andrew HackettDepartment of Drug Metabolism, Huntingdon Life Sciences, Huntingdon, Cambridgeshire, UK
,
Rajdeep BenningHammersmith Medicines Research, London, UK
&
Steve WarringtonHammersmith Medicines Research, London, UK
Pages 432-442 | Received 17 Aug 2012, Accepted 15 Sep 2012, Published online: 18 Oct 2012

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Yukihisa S. Watanabe, Yoshika Yasuda, Yuko Kojima, Shino Okada, Tomoko Motoyama, Ryo Takahashi & Mitsuru Oka. (2015) Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions. Journal of Enzyme Inhibition and Medicinal Chemistry 30:6, pages 981-988.
Read now
Meng-Wong Taing, Felicity J Rose & Jonathan P Whitehead. (2014) GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?. Drug Design, Development and Therapy 8, pages 677-688.
Read now
Theodosios D Filippatos, Vasilios G Athyros & Moses S Elisaf. (2014) The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 787-812.
Read now
Maliheh Safavi, Alireza Foroumadi & Mohammad Abdollahi. (2013) The importance of synthetic drugs for type 2 diabetes drug discovery. Expert Opinion on Drug Discovery 8:11, pages 1339-1363.
Read now
Avivit Cahn & Itamar Raz. (2013) Emerging gliptins for type 2 diabetes. Expert Opinion on Emerging Drugs 18:2, pages 245-258.
Read now

Articles from other publishers (24)

Qing Li, Xiaoyan Deng, Yan-Jun Xu & Lin Dong. (2023) Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants. Journal of Medicinal Chemistry 66:17, pages 11593-11631.
Crossref
Anna Gumieniczek & Anna Berecka-Rycerz. (2023) Metabolism and Chemical Degradation of New Antidiabetic Drugs (Part II): A Review of Analytical Approaches for Analysis of Gliptins. Biomedicines 11:7, pages 1956.
Crossref
Cristina Bouzas, Rosario Pastor, Silvia Garcia, Margalida Monserrat-Mesquida, Miguel Ángel Martínez-González, Jordi Salas-Salvadó, Dolores Corella, Albert Goday, J. Alfredo Martínez, Ángel M. Alonso-Gómez, Olga Fernández-Barceló, Jesús Vioque, Dora Romaguera, José Lopez-Miranda, Ramón Estruch, Francisco J. Tinahones, José Lapetra, Lluís Serra-Majem, Blanca Riquelme-Gallego, Vicente Martín-Sánchez, Xavier Pintó, Miguel Delgado-Rodriguez, Pilar Matía, Josep Vidal, Jersy-Jair Cardenas-Salas, Lidia Daimiel, Emilio Ros, Estefanía Toledo, Josep M. Manzanares, Inmaculada Gonzalez-Monge, Miguel-Ángel Muñoz, Diego Martinez-Urbistondo, Lucas Tojal-Sierra, Carlos Muñoz-Bravo, Salvador Miralles-Gisbert, Marian Martin, Antonio García-Ríos, Sara Castro-Barquero, José Carlos Fernández-García, José Manuel Santos-Lozano, F. Javier Basterra-Gortari, Liliana Gutiérrez-Carrasquilla, Patricia Guillem-Saiz, Alba Satorres, Itziar Abete, Carolina Sorto-Sanchez, Javier Díez-Espino, Nancy Babio, Montse Fitó & Josep A. Tur. (2023) Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome. Biomedicine & Pharmacotherapy 161, pages 114561.
Crossref
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, A. V. Strygin, Yu. V. Gorbunova, E. V. Volotova, I. E. Makarenko, V. B. Saparova, R. V. Drai & V. I. Petrov. (2023) Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use. Pharmacy & Pharmacology 11:1, pages 19-47.
Crossref
Sang-Yong Kim & Sungrae Kim. (2022) Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study. Diabetes Therapy 14:1, pages 109-121.
Crossref
Nasr E. Nasr & Kadry M. Sadek. (2022) Role and mechanism(s) of incretin-dependent therapies for treating diabetes mellitus. Environmental Science and Pollution Research 29:13, pages 18408-18422.
Crossref
Namyi Gu, Sang-In Park, Hyewon Chung, Xuanyou Jin, SeungHwan Lee & Tae-Eun Kim. (2020) Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. Translational and Clinical Pharmacology 28:1, pages 17.
Crossref
Maryam Rameshrad, Bibi Marjan Razavi, Gordon A. A. Ferns & Hossein Hosseinzadeh. (2019) Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning. DARU Journal of Pharmaceutical Sciences 27:1, pages 341-360.
Crossref
Naina Mohamed Pakkir Maideen. (2019) Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump. World Journal of Meta-Analysis 7:4, pages 156-161.
Crossref
Fandi Kong, Xiaoyan Pang, Jihui Zhao, Pan Deng, Mingyue Zheng, Dafang Zhong & Xiaoyan Chen. (2019) Hydrolytic Metabolism of Cyanopyrrolidine DPP-4 Inhibitors Mediated by Dipeptidyl Peptidases. Drug Metabolism and Disposition 47:3, pages 238-248.
Crossref
Charu P. Pandya & Sadhana J. Rajput. (2018) Stress Degradation Studies of Anagliptin, Development of Validated Stability Indicating Method, Degradation Kinetics Study, Identification and Isolation of Degradation Products. Chromatographia 81:11, pages 1533-1550.
Crossref
Katsuhiko Mizuno, Kenji Takeuchi, Ken Umehara & Miki Nakajima. (2018) Identification of a novel metabolite of vildagliptin in humans: Cysteine targets the nitrile moiety to form a thiazoline ring. Biochemical Pharmacology 156, pages 312-321.
Crossref
Shandilya Mahamuni Baira, Dilep Kumar Sigalapalli, Nagendra Babu Bathini, Srinivas R.M.V.N Kumar Talluri. (2018) LC/QTOF/MS/MS characterization, molecular docking and in silico toxicity prediction studies on degradation products of anagliptin. Journal of Pharmaceutical and Biomedical Analysis 159, pages 92-99.
Crossref
Anton Ivanyuk, Françoise Livio, Jérôme Biollaz & Thierry Buclin. (2017) Renal Drug Transporters and Drug Interactions. Clinical Pharmacokinetics 56:8, pages 825-892.
Crossref
Ayman F. El‐Kattan. 2017. Oral Bioavailability Assessment. Oral Bioavailability Assessment 77 138 .
T. Biftu & R. SinhaRoy. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III 512 555 .
C. F. Deacon & H. E. Lebovitz. (2016) Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism 18:4, pages 333-347.
Crossref
Enrique Z. Fisman & Alexander Tenenbaum. (2015) Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovascular Diabetology 14:1.
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
S.-M. Jin, S. W. Park, K.-H. Yoon, K. W. Min, K.-H. Song, K. S. Park, J.-Y. Park, I. B. Park, C. H. Chung, S. H. Baik, S. H. Choi, H. W. Lee, I.-K. Lee, D.-M. Kim & M.-K. Lee. (2015) Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension. Diabetes, Obesity and Metabolism 17:5, pages 511-515.
Crossref
Mitsutoshi Asakura, Hideaki Fujii, Koichiro Atsuda, Tomoo Itoh & Ryoichi Fujiwara. (2015) Dipeptidyl Peptidase-4 Greatly Contributes to the Hydrolysis of Vildagliptin in Human Liver. Drug Metabolism and Disposition 43:4, pages 477-484.
Crossref
Hae Kyung Yang, Kyung Wan Min, Sung Woo Park, Choon Hee Chung, Kyong Soo Park, Sung Hee Choi, Ki-Ho Song, Doo-Man Kim, Moon-Kyu Lee, Yeon-Ah Sung, Sei Hyun Baik, In Joo Kim, Bong-Soo Cha, Jeong Hyun Park, Yu Bae Ahn, In-Kyu Lee, Soon Jib Yoo, Jaetaek Kim, Ie Byung Park, Tae Sun Park & Kun-Ho Yoon. (2015) A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes. Endocrine Journal 62:5, pages 449-462.
Crossref
Shinji Furuta, Miyuki Tamura, Hiroko Hirooka, Yukie Mizuno, Mika Miyoshi & Yoshiyuki Furuta. (2013) Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs. European Journal of Drug Metabolism and Pharmacokinetics 38:2, pages 87-96.
Crossref
Joanne Bronson, Amelia Black, T. G. Murali Dhar, Bruce A. Ellsworth & J. Robert Merritt. 2013. 471 546 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.